These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19551702)

  • 1. Electrocardiographic monitoring for QT prolongation in patients treated with ziprasidone--a claims database approach.
    Lin YL; Wu YC; Tsai GF
    Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):842-7. PubMed ID: 19551702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
    Kohen I; Preval H; Southard R; Francis A
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk of QTc prolongation due to combination of ziprasidone and quetiapine].
    Minov C
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S142-4. PubMed ID: 15570533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose ziprasidone associated with QT interval prolongation.
    Witsil JC; Zell-Kanter M; Mycyk MB
    Am J Emerg Med; 2012 Jun; 30(5):837.e1-2. PubMed ID: 21641143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations.
    Kelly DL; Love RC
    Psychopharmacol Bull; 2001; 35(4):66-79. PubMed ID: 12397857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study.
    Blair J; Scahill L; State M; Martin A
    J Am Acad Child Adolesc Psychiatry; 2005 Jan; 44(1):73-9. PubMed ID: 15608546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis.
    Kim E; Maclean R; Ammerman D; Jing Y; Pikalov A; You M; Van-Tran Q; L'Italien G
    Clin Ther; 2009 Apr; 31(4):836-48. PubMed ID: 19446157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [QTc-interval prolongation in therapy with atypical antipsychotics--results of an open, non-randomized survey].
    Finzel M; Fric M; Laux G
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S178-80. PubMed ID: 15570546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. Clinical article.
    Scott LK; Green R; McCarthy PJ; Conrad SA
    J Neurosurg Pediatr; 2009 Jun; 3(6):484-7. PubMed ID: 19485732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective observational multi-poison center study of ziprasidone exposures.
    Klein-Schwartz W; Lofton AL; Benson BE; Spiller HA; Crouch BI
    Clin Toxicol (Phila); 2007; 45(7):782-6. PubMed ID: 17926152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation.
    Kirchhof P; Franz MR; Bardai A; Wilde AM
    J Am Coll Cardiol; 2009 Jul; 54(2):143-9. PubMed ID: 19573731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An algorithm for continuous real-time QT interval monitoring.
    Helfenbein ED; Zhou SH; Lindauer JM; Field DQ; Gregg RE; Wang JJ; Kresge SS; Michaud FP
    J Electrocardiol; 2006 Oct; 39(4 Suppl):S123-7. PubMed ID: 16920145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychotropic drugs associated with corrected QT interval prolongation.
    van Noord C; Straus SM; Sturkenboom MC; Hofman A; Aarnoudse AJ; Bagnardi V; Kors JA; Newton-Cheh C; Witteman JC; Stricker BH
    J Clin Psychopharmacol; 2009 Feb; 29(1):9-15. PubMed ID: 19142100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ziprasidone-associated pedal edema in the treatment of schizophrenia.
    Ku HL; Su TP; Chou YH
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):963-4. PubMed ID: 16624468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen-induced QT interval prolongation.
    Slovacek L; Ansorgova V; Macingova Z; Haman L; Petera J
    J Clin Pharm Ther; 2008 Aug; 33(4):453-5. PubMed ID: 18613864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone overdose: cases recorded in the database of Pfizer-Spain and literature review.
    Gómez-Criado MS; Bernardo M; Florez Td; Gutiérrez JR; Gandía R; Ayani I
    Pharmacotherapy; 2005 Nov; 25(11):1660-5. PubMed ID: 16232029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inadvertent administration of intravenous ziprasidone leading to bradycardia and QT interval prolongation.
    Bentley ML; Biscardi FH; Butcher C; Levitov A
    Ann Pharmacother; 2008 Jun; 42(6):902-3. PubMed ID: 18477728
    [No Abstract]   [Full Text] [Related]  

  • 18. Ziprasidone in the treatment of delayed carbon monoxide encephalopathy.
    Hu MC; Shiah IS; Yeh CB; Chen HK; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):755-7. PubMed ID: 16581170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice.
    Fukushiro DF; Carvalho Rde C; Ricardo VP; Alvarez Jdo N; Ribeiro LT; Frussa-Filho R
    Brain Res Bull; 2008 Sep; 77(2-3):124-8. PubMed ID: 18721669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of ANOVA to estimate inter- and intra-reader variability for a group of readers in thorough QT/QTc studies.
    Natekar M; Mahajan V; Satra A; O'Kelly M; Karnad DR
    Clin Pharmacol Ther; 2008 Mar; 83(3):489-91. PubMed ID: 18183035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.